Mepolizumab (new indication: chronic rhinosinusitis with nasal polyps)

Subject:

• Active Substance: Mepolizumab
• Name: Nucala^®
• Therapeutic area: Rhinosinusitis
• Pharmaceutical company: GlaxoSmithKline GmbH & Co. KG

Time table:

• Start: 01.12.2021
• Final decision by G-BA: 19.05.2022

Final decision:

• No addtional benefit proved